Matching articles for "edaravone"

Relyvrio for ALS

   
The Medical Letter on Drugs and Therapeutics • November 28, 2022;  (Issue 1664)
The FDA has approved Relyvrio (Amylyx), a fixed-dose combination of sodium phenylbutyrate and taurursodiol, for treatment of amyotrophic lateral sclerosis (ALS). Sodium phenylbutyrate (Buphenyl, and others)...
The FDA has approved Relyvrio (Amylyx), a fixed-dose combination of sodium phenylbutyrate and taurursodiol, for treatment of amyotrophic lateral sclerosis (ALS). Sodium phenylbutyrate (Buphenyl, and others) has been available by prescription for years for treatment of urea cycle disorders. Taurursodiol (tauroursodeoxycholic acid), a derivative of ursodiol, is an over-the-counter bile acid supplement claimed to have neuroprotective benefits. Relyvrio is the third drug to be approved in the US for treatment of ALS; riluzole (Rilutek, and others) and edaravone (Radicava, Radicava ORS) were approved earlier.
Med Lett Drugs Ther. 2022 Nov 28;64(1664):190-1 | Show Full IntroductionHide Full Introduction

In Brief: Edaravone Oral Suspension (Radicava ORS) for ALS (online only)

   
The Medical Letter on Drugs and Therapeutics • September 5, 2022;  (Issue 1658)
Radicava ORS, an oral suspension formulation of the free radical scavenger edaravone (Mitsubishi Tanabe Pharma), has been approved by the FDA for treatment of amyotrophic lateral sclerosis (ALS). An IV...
Radicava ORS, an oral suspension formulation of the free radical scavenger edaravone (Mitsubishi Tanabe Pharma), has been approved by the FDA for treatment of amyotrophic lateral sclerosis (ALS). An IV formulation of edaravone (Radicava) has been available since 2017.
Med Lett Drugs Ther. 2022 Sep 5;64(1658):e1 | Show Full IntroductionHide Full Introduction

Edaravone (Radicava) for ALS

   
The Medical Letter on Drugs and Therapeutics • November 6, 2017;  (Issue 1533)
The FDA has approved edaravone (Radicava – Mitsubishi Tanabe Pharma) for treatment of amyotrophic lateral sclerosis (ALS). It is the second drug to be approved in the US for this indication; riluzole...
The FDA has approved edaravone (Radicava – Mitsubishi Tanabe Pharma) for treatment of amyotrophic lateral sclerosis (ALS). It is the second drug to be approved in the US for this indication; riluzole (Rilutek, and generics) was approved in 1995. Edaravone was approved for treatment of ALS as Radicut in Japan and South Korea in 2015. It has been used in Japan and other Asian countries since 2001 for treatment of acute ischemic stroke.
Med Lett Drugs Ther. 2017 Nov 6;59(1533):180-2 | Show Full IntroductionHide Full Introduction